In the rapidly evolving landscape of healthcare, Pharma Patient Assistance Programs (PAP) have been a lifeline for many patients seeking access to essential medications. These programs aim to help ...
On June 17, 2024, the U.S. Department of Health and Human Services Office of Inspector General (“OIG”) posted a favorable Advisory Opinion 24-03 (“AO 24-03”) involving a pharmaceutical manufacturer’s ...
We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...
When Gury Doshi, MD, learned that a patient’s insurance didn’t cover her breast cancer medication, Doshi had a potential workaround. The patient could try to bypass the insurer and access the drug at ...
You may qualify for free Restasis through the drug’s manufacturer, myAbbVie Assist. That said, you won’t use your Medicare coverage. Restasis (cyclosporine), a brand-name eye drop for chronic dry eyes ...
One of the most powerful components of the Affordable Care Act (ACA) was the mandate that nonprofit hospitals provide an income-based financial assistance program. But 10 years after the passage of ...
Efficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients With Hormone Receptor–Positive Advanced Breast Cancer Eligible patients were diagnosed with cancer and ...
The U.S. government’s patient assistance program enables eligible Medicare recipients to receive Paxlovid at no cost until December 31, 2025. However, also in 2025, the FDA revoked the emergency ...
Recently, the Department of Health and Human Services Office of Inspector General (“OIG”) released Advisory Opinion (“Opinion”) 24-02 regarding patient assistance funds provided by a non-profit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback